Datasets:

Ichlibitiche
/

csa-clinical-stage-asset-intelligence-sample

event_date string	ticker string	asset string	event_type string	event_window string	date_precision string	confidence string	source string	nct_id string	source_url string
2026-07-18	BMY	mezigdomide	READOUT	Jul 18, 2026	day	medium	clinicaltrials	NCT05552976	https://clinicaltrials.gov/study/NCT05552976
2026-07-25	BMY	deucravacitinib	READOUT	Jul 25, 2026	day	medium	clinicaltrials	NCT04036435	https://clinicaltrials.gov/study/NCT04036435
2026-07-27	REGN	fianlimab	READOUT	Jul 27, 2026	day	medium	clinicaltrials	NCT05608291	https://clinicaltrials.gov/study/NCT05608291
2026-07-31	HRMY	pitolisant	READOUT	Jul 2026	month	medium	clinicaltrials	NCT06366464	https://clinicaltrials.gov/study/NCT06366464
2026-07-31	LXRX	sotagliflozin	READOUT	Jul 2026	month	medium	clinicaltrials	NCT06481891	https://clinicaltrials.gov/study/NCT06481891
2026-07-31	JAZZ	zanidatamab	READOUT	Jul 31, 2026	day	medium	clinicaltrials	NCT05152147	https://clinicaltrials.gov/study/NCT05152147
2026-08-01	MRK	tulisokibart	READOUT	Aug 1, 2026	day	medium	clinicaltrials	NCT06052059	https://clinicaltrials.gov/study/NCT06052059
2026-08-24	AZN	camizestrant	READOUT	Aug 24, 2026	day	medium	clinicaltrials	NCT04711252	https://clinicaltrials.gov/study/NCT04711252
2026-08-30	PFE	elranatamab	READOUT	Aug 30, 2026	day	medium	clinicaltrials	NCT06152575	https://clinicaltrials.gov/study/NCT06152575
2026-08-31	PHVS	deucrictibant	READOUT	Aug 2026	month	medium	clinicaltrials	NCT06669754	https://clinicaltrials.gov/study/NCT06669754
2026-08-31	SBFM	lerotinib	READOUT	Aug 2026	month	medium	clinicaltrials	NCT04415853	https://clinicaltrials.gov/study/NCT04415853
2026-08-31	SLGL	patidegib	READOUT	Aug 2026	month	medium	clinicaltrials	NCT06050122	https://clinicaltrials.gov/study/NCT06050122
2026-08-31	LLY	retatrutide	READOUT	Aug 2026	month	medium	clinicaltrials	NCT06260722	https://clinicaltrials.gov/study/NCT06260722
2026-09-01	INCY	tafasitamab	READOUT	Sep 1, 2026	day	medium	clinicaltrials	NCT04824092	https://clinicaltrials.gov/study/NCT04824092
2026-09-27	BIIB	litifilimab	READOUT	Sep 27, 2026	day	medium	clinicaltrials	NCT04961567	https://clinicaltrials.gov/study/NCT04961567
2026-09-28	MLTX	sonelokimab	READOUT	Sep 28, 2026	day	medium	clinicaltrials	NCT06768671	https://clinicaltrials.gov/study/NCT06768671
2026-09-30	AZN	datopotamab deruxtecan	READOUT	Sep 30, 2026	day	medium	clinicaltrials	NCT06417814	https://clinicaltrials.gov/study/NCT06417814
2026-09-30	KURA	daunorubicin	READOUT	Sep 30, 2026	day	medium	clinicaltrials	NCT03117751	https://clinicaltrials.gov/study/NCT03117751
2026-09-30	DAN	erwinia asparaginase	READOUT	Sep 30, 2026	day	medium	clinicaltrials	NCT03117751	https://clinicaltrials.gov/study/NCT03117751
2026-09-30	BIIB	litifilimab	READOUT	Sep 30, 2026	day	medium	clinicaltrials	NCT04895241	https://clinicaltrials.gov/study/NCT04895241
2026-09-30	DAN	mercaptopurine	READOUT	Sep 30, 2026	day	medium	clinicaltrials	NCT03117751	https://clinicaltrials.gov/study/NCT03117751
2026-09-30	AZN	monalizumab	READOUT	Sep 30, 2026	day	medium	clinicaltrials	NCT05221840	https://clinicaltrials.gov/study/NCT05221840
2026-09-30	DAN	nelarabine	READOUT	Sep 30, 2026	day	medium	clinicaltrials	NCT03117751	https://clinicaltrials.gov/study/NCT03117751
2026-09-30	AZN	oleclumab	READOUT	Sep 30, 2026	day	medium	clinicaltrials	NCT05221840	https://clinicaltrials.gov/study/NCT05221840
2026-09-30	DAN	pegaspargase	READOUT	Sep 30, 2026	day	medium	clinicaltrials	NCT03117751	https://clinicaltrials.gov/study/NCT03117751
2026-10-19	BMY	deucravacitinib	READOUT	Oct 19, 2026	day	medium	clinicaltrials	NCT05617677	https://clinicaltrials.gov/study/NCT05617677
2026-10-20	BIIB	litifilimab	READOUT	Oct 20, 2026	day	medium	clinicaltrials	NCT05531565	https://clinicaltrials.gov/study/NCT05531565
2026-10-26	NVS	inclisiran	READOUT	Oct 26, 2026	day	medium	clinicaltrials	NCT05360446	https://clinicaltrials.gov/study/NCT05360446
2026-10-28	MRK	belzutifan	READOUT	Oct 28, 2026	day	medium	clinicaltrials	NCT05239728	https://clinicaltrials.gov/study/NCT05239728
2026-10-29	MRK	belzutifan	READOUT	Oct 29, 2026	day	medium	clinicaltrials	NCT04736706	https://clinicaltrials.gov/study/NCT04736706
2026-10-31	NUVL	alectinib	READOUT	Oct 31, 2026	day	medium	clinicaltrials	NCT03178552	https://clinicaltrials.gov/study/NCT03178552
2026-10-31	VTRS	cenerimod	READOUT	Oct 31, 2026	day	medium	clinicaltrials	NCT05648500	https://clinicaltrials.gov/study/NCT05648500
2026-10-31	IMMP	eftilagimod alpha	READOUT	Oct 31, 2026	day	medium	clinicaltrials	NCT05747794	https://clinicaltrials.gov/study/NCT05747794
2026-10-31	NVS	inclisiran	READOUT	Oct 2026	month	medium	clinicaltrials	NCT03705234	https://clinicaltrials.gov/study/NCT03705234
2026-10-31	SBFM	minoxidil	READOUT	Oct 2026	month	medium	clinicaltrials	NCT05888922	https://clinicaltrials.gov/study/NCT05888922
2026-10-31	LLY	retatrutide	READOUT	Oct 2026	month	medium	clinicaltrials	NCT06297603	https://clinicaltrials.gov/study/NCT06297603
2026-10-31	OGN	tapinarof	READOUT	Oct 2026	month	medium	clinicaltrials	NCT05172726	https://clinicaltrials.gov/study/NCT05172726
2026-11-13	COGT	midazolam	READOUT	Nov 13, 2026	day	medium	clinicaltrials	NCT05646862	https://clinicaltrials.gov/study/NCT05646862
2026-11-30	CGON	cretostimogene grenadenorepvec	READOUT	Nov 2026	month	medium	clinicaltrials	NCT06111235	https://clinicaltrials.gov/study/NCT06111235
2026-11-30	DAN	erwinia asparaginase	READOUT	Nov 30, 2026	day	medium	clinicaltrials	NCT03020030	https://clinicaltrials.gov/study/NCT03020030
2026-11-30	NAMS	obicetrapib	READOUT	Nov 2026	month	medium	clinicaltrials	NCT05202509	https://clinicaltrials.gov/study/NCT05202509
2026-11-30	LLY	orforglipron	READOUT	Nov 2026	month	medium	clinicaltrials	NCT06649045	https://clinicaltrials.gov/study/NCT06649045
2026-11-30	DAN	pegaspargase	READOUT	Nov 30, 2026	day	medium	clinicaltrials	NCT03020030	https://clinicaltrials.gov/study/NCT03020030
2026-11-30	LLY	tirzepatide	READOUT	Nov 2026	month	medium	clinicaltrials	NCT06914895	https://clinicaltrials.gov/study/NCT06914895
2026-12-01	VNDA	tradipitant	READOUT	Dec 1, 2026	day	medium	clinicaltrials	NCT07446439	https://clinicaltrials.gov/study/NCT07446439
2026-12-02	MRK	enlicitide decanoate	READOUT	Dec 2, 2026	day	medium	clinicaltrials	NCT07216482	https://clinicaltrials.gov/study/NCT07216482
2026-12-02	PFE	mevrometostat	READOUT	Dec 2, 2026	day	medium	clinicaltrials	NCT06629779	https://clinicaltrials.gov/study/NCT06629779
2026-12-02	PFE	ritlecitinib higher	READOUT	Dec 2, 2026	day	medium	clinicaltrials	NCT07029711	https://clinicaltrials.gov/study/NCT07029711
2026-12-02	PFE	ritlecitinib lower	READOUT	Dec 2, 2026	day	medium	clinicaltrials	NCT07029711	https://clinicaltrials.gov/study/NCT07029711
2026-12-02	MRK	rosuvastatin calcium	READOUT	Dec 2, 2026	day	medium	clinicaltrials	NCT07216482	https://clinicaltrials.gov/study/NCT07216482
2026-12-21	PFE	ritlecitinib	READOUT	Dec 21, 2026	day	medium	clinicaltrials	NCT06873945	https://clinicaltrials.gov/study/NCT06873945
2026-12-26	INCY	povorcitinib	READOUT	Dec 26, 2026	day	medium	clinicaltrials	NCT06212999	https://clinicaltrials.gov/study/NCT06212999
2026-12-30	INTS	pazopanib	READOUT	Dec 30, 2026	day	medium	clinicaltrials	NCT03592472	https://clinicaltrials.gov/study/NCT03592472
2026-12-30	PFE	vepdegestrant	READOUT	Dec 30, 2026	day	medium	clinicaltrials	NCT05909397	https://clinicaltrials.gov/study/NCT05909397
2026-12-31	PFE	axitinib	READOUT	Dec 31, 2026	day	medium	clinicaltrials	NCT05059522	https://clinicaltrials.gov/study/NCT05059522
2026-12-31	AZN	darolutamide	READOUT	Dec 2026	month	medium	clinicaltrials	NCT03903835	https://clinicaltrials.gov/study/NCT03903835
2026-12-31	PFE	disitamab vedotin	READOUT	Dec 31, 2026	day	medium	clinicaltrials	NCT05302284	https://clinicaltrials.gov/study/NCT05302284
2026-12-31	IONS	donidalorsen	READOUT	Dec 2026	month	medium	clinicaltrials	NCT05392114	https://clinicaltrials.gov/study/NCT05392114
2026-12-31	MRK	ibrutinib	READOUT	Dec 31, 2026	day	medium	clinicaltrials	NCT01804686	https://clinicaltrials.gov/study/NCT01804686
2026-12-31	SMMT	ivonescimab	READOUT	Dec 2026	month	medium	clinicaltrials	NCT06767527	https://clinicaltrials.gov/study/NCT06767527
2026-12-31	PFE	lorlatanib	READOUT	Dec 31, 2026	day	medium	clinicaltrials	NCT05059522	https://clinicaltrials.gov/study/NCT05059522
2026-12-31	ABBV	lutikizumab	READOUT	Dec 2026	month	medium	clinicaltrials	NCT06468228	https://clinicaltrials.gov/study/NCT06468228
2026-12-31	SNY	migalastat	READOUT	Dec 31, 2026	day	medium	clinicaltrials	NCT04020055	https://clinicaltrials.gov/study/NCT04020055
2026-12-31	GNLX	olvimulogene nanivacirepvec	READOUT	Dec 2026	month	medium	clinicaltrials	NCT05281471	https://clinicaltrials.gov/study/NCT05281471
2026-12-31	UTHR	ralinepag	READOUT	Dec 2026	month	medium	clinicaltrials	NCT03683186	https://clinicaltrials.gov/study/NCT03683186
2026-12-31	DMAC	recombinant human tissue kallikrein	READOUT	Dec 2026	month	medium	clinicaltrials	NCT05065216	https://clinicaltrials.gov/study/NCT05065216
2026-12-31	LLY	retatrutide	READOUT	Dec 2026	month	medium	clinicaltrials	NCT06662383	https://clinicaltrials.gov/study/NCT06662383
2026-12-31	GILD	sacituzumab govitecan hziy	READOUT	Dec 2026	month	medium	clinicaltrials	NCT04639986	https://clinicaltrials.gov/study/NCT04639986
2026-12-31	PFE	talazoparib	READOUT	Dec 31, 2026	day	medium	clinicaltrials	NCT05059522	https://clinicaltrials.gov/study/NCT05059522
2026-12-31	VOR	telitacicept	READOUT	Dec 31, 2026	day	medium	clinicaltrials	NCT07249632	https://clinicaltrials.gov/study/NCT07249632
2026-12-31	PFE	utomilumab	READOUT	Dec 31, 2026	day	medium	clinicaltrials	NCT05059522	https://clinicaltrials.gov/study/NCT05059522
2027-01-04	AZN	laroprovstat	READOUT	Jan 4, 2027	day	medium	clinicaltrials	NCT07000136	https://clinicaltrials.gov/study/NCT07000136
2027-01-04	MRK	rescue medications	READOUT	Jan 4, 2027	day	medium	clinicaltrials	NCT06356311	https://clinicaltrials.gov/study/NCT06356311
2027-01-04	MRK	supportive care measures	READOUT	Jan 4, 2027	day	medium	clinicaltrials	NCT06356311	https://clinicaltrials.gov/study/NCT06356311
2027-01-10	BMY	mezigdomide	READOUT	Jan 10, 2027	day	medium	clinicaltrials	NCT05519085	https://clinicaltrials.gov/study/NCT05519085
2027-01-11	AZN	laroprovstat	READOUT	Jan 11, 2027	day	medium	clinicaltrials	NCT07000123	https://clinicaltrials.gov/study/NCT07000123
2027-01-13	SMMT	ivonescimab	READOUT	Jan 13, 2027	day	medium	clinicaltrials	NCT06951503	https://clinicaltrials.gov/study/NCT06951503
2027-01-15	IDYA	darovasertib	READOUT	Jan 15, 2027	day	medium	clinicaltrials	NCT05987332	https://clinicaltrials.gov/study/NCT05987332
2027-01-15	MLTX	sonelokimab	READOUT	Jan 15, 2027	day	medium	clinicaltrials	NCT06641089	https://clinicaltrials.gov/study/NCT06641089
2027-01-21	AMGN	maridebart cafraglutide	READOUT	Jan 21, 2027	day	medium	clinicaltrials	NCT06858839	https://clinicaltrials.gov/study/NCT06858839
2027-01-29	PFE	disitamab vedotin	READOUT	Jan 29, 2027	day	medium	clinicaltrials	NCT05911295	https://clinicaltrials.gov/study/NCT05911295
2027-02-04	MLTX	sonelokimab	READOUT	Feb 4, 2027	day	medium	clinicaltrials	NCT06641076	https://clinicaltrials.gov/study/NCT06641076
2027-02-11	NVS	inclisiran	READOUT	Feb 11, 2027	day	medium	clinicaltrials	NCT07102628	https://clinicaltrials.gov/study/NCT07102628
2027-02-14	LLY	tirzepatide	READOUT	Feb 14, 2027	day	medium	clinicaltrials	NCT07481747	https://clinicaltrials.gov/study/NCT07481747
2027-02-22	AZN	laroprovstat	READOUT	Feb 22, 2027	day	medium	clinicaltrials	NCT06834932	https://clinicaltrials.gov/study/NCT06834932
2027-02-26	AZN	anifrolumab	READOUT	Feb 26, 2027	day	medium	clinicaltrials	NCT05138133	https://clinicaltrials.gov/study/NCT05138133
2027-02-28	LLY	orforglipron	READOUT	Feb 2027	month	medium	clinicaltrials	NCT06672549	https://clinicaltrials.gov/study/NCT06672549
2027-02-28	GMAB	rina	READOUT	Feb 2027	month	medium	clinicaltrials	NCT06619236	https://clinicaltrials.gov/study/NCT06619236
2027-02-28	GILD	sacituzumab govitecan hziy	READOUT	Feb 2027	month	medium	clinicaltrials	NCT05382286	https://clinicaltrials.gov/study/NCT05382286
2027-03-01	NVO	cagrilintide	READOUT	Mar 1, 2027	day	medium	clinicaltrials	NCT07011667	https://clinicaltrials.gov/study/NCT07011667
2027-03-13	RYTM	setmelanotide	READOUT	Mar 13, 2027	day	medium	clinicaltrials	NCT06760546	https://clinicaltrials.gov/study/NCT06760546
2027-03-18	MRK	ibrutinib	READOUT	Mar 18, 2027	day	medium	clinicaltrials	NCT04212013	https://clinicaltrials.gov/study/NCT04212013
2027-03-22	REGN	fianlimab	READOUT	Mar 22, 2027	day	medium	clinicaltrials	NCT06246916	https://clinicaltrials.gov/study/NCT06246916
2027-03-24	NVS	ianalumab	READOUT	Mar 24, 2027	day	medium	clinicaltrials	NCT05639114	https://clinicaltrials.gov/study/NCT05639114
2027-03-31	ARGX	efgartigimod	READOUT	Mar 2027	month	medium	clinicaltrials	NCT04833894	https://clinicaltrials.gov/study/NCT04833894
2027-03-31	IONS	olezarsen	READOUT	Mar 2027	month	medium	clinicaltrials	NCT05681351	https://clinicaltrials.gov/study/NCT05681351
2027-03-31	AAPG	olverembatinib	READOUT	Mar 31, 2027	day	medium	clinicaltrials	NCT06640361	https://clinicaltrials.gov/study/NCT06640361
2027-03-31	MDGL	resmetirom	READOUT	Mar 2027	month	medium	clinicaltrials	NCT04951219	https://clinicaltrials.gov/study/NCT04951219
2027-03-31	AZN	rezvilutamide	READOUT	Mar 2027	month	medium	clinicaltrials	NCT07241416	https://clinicaltrials.gov/study/NCT07241416
2027-03-31	PFE	ritlecitinib	READOUT	Mar 31, 2027	day	medium	clinicaltrials	NCT06163326	https://clinicaltrials.gov/study/NCT06163326

End of preview. Expand in Data Studio

CSA — Clinical-Stage Asset Intelligence · Free Sample

Clinical trials, FDA, and SEC — linked to the drug asset and the listed sponsor, with a forward catalyst calendar. This is a free 150-row sample of the nearest-term catalysts; the full snapshot carries 2,103 forward catalysts across 139 listed sponsors and 1,841 resolved assets.

Data, not investment advice. CSA is information, not a recommendation to buy, sell, or hold any security. Estimated catalyst dates (e.g. protocol primary-completion dates) routinely slip and are graded by confidence — verify anything material against the source_url on each row.

What's inside

File	Rows	What it is
`catalyst_calendar_sample.csv`	150	Nearest-term forward catalysts (2026-07-18 → 2027-09-01), 108 assets, 50 sponsors.
`asset_master_sample.csv`	464	The asset ↔ trial ↔ sponsor ↔ ticker rows behind them.
`*_sample.json`	—	The same tables as records-oriented JSON.

`catalyst_calendar_sample.csv`

event_date · ticker · asset · event_type (PDUFA / READOUT / …) · event_window · date_precision · confidence · source (sec_8k / clinicaltrials) · nct_id · source_url.

`asset_master_sample.csv`

asset · nct_id · phase · status · primary_completion · conditions · arm_role · sponsor_raw · company_name · ticker.

How it's built

Active-moiety resolution keys each asset to its FDA-registered UNII set (GSRS), not fuzzy names — audited to zero cross-molecule merges.
Sponsor → listed ticker through acquisitions, to the primary US listing.
Dual-channel catalysts: SEC 8-K disclosure text + active late-phase ClinicalTrials.gov protocol readouts. Every row carries its source.

Sample scope: active, industry-sponsored, Phase 3 trials in cardiometabolic, oncology and immunology. Asset names are normalized for readability; the sample is curated to clinical-stage, single-sponsor assets.

Sources & license

All primary sources are U.S. Government / public domain: ClinicalTrials.gov, openFDA, SEC EDGAR, GSRS/UNII. This sample is released under CC-BY-NC-4.0 (free to use and share with attribution, not to re-sell). See SAMPLE_LICENSE.md.

Get the full dataset

The complete, commercially-licensed snapshot (all 2,103 catalysts, CSV + JSON, monthly editions + delta feed) → https://csa-public.pages.dev · code: https://github.com/CSA-pub/CSA-public · contact: https://csa-public.pages.dev/#contact

Downloads last month: 8